GlassScriptPhysician profile
Deborah Revell
NPI 1366887507
$2,709.42
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $461 · 2022: $1,147 · 2023: $1,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $814.19 | 2021-2023 | |
| Janssen Biotech, INC. | $379.22 | 2021-2023 | Stelara, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.12 | 2021-2023 | Xifaxan, Plenvu |
| Qol Medical, LLC | $199.56 | 2021-2023 | Sucraid |
| Merck Sharp & Dohme LLC | $135.39 | 2022-2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $135.20 | 2021-2023 | Ocaliva |
| Pfizer INC. | $115.69 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.96 | 2021-2023 | Entyvio |
| Redhill Biopharma INC. | $80.69 | 2021 | |
| Daiichi Sankyo INC. | $72.64 | 2021-2023 | Injectafer |
| Evoke Pharma, INC. | $60.47 | 2021-2022 | |
| Braintree Laboratories, INC. | $60.21 | 2022-2023 | Sutab |
| Amgen INC. | $52.59 | 2023 | Amjevita |
| Nestle Healthcare Nutrition INC. | $43.18 | 2022 | |
| Ferring Pharmaceuticals INC. | $40.55 | 2021-2023 | Rebyota |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $38.91 | 2022 | |
| Organon LLC | $36.12 | 2022-2023 | Renflexis |
| Celgene Corporation | $30.80 | 2021-2023 | Zeposia |
| Fresenius Kabi USA, LLC | $29.64 | 2023 | Idacio |
| Ironwood Pharmaceuticals, INC | $23.16 | 2022 | |
| Sandoz INC. | $15.13 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Revell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.